TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02564263
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle
Study: NCT00808704
Drug: recombinant human erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
Study: NCT02753114
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
Study: NCT00783237
Drug: Mometasone
Normalized name: Mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
Study: NCT00728793
Drug: CUDC-101
Normalized name: CUDC-101
DrugBank: CUDC-101 (DB12174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
Study: NCT02419105
Drug: Colecalciferol
Normalized name: colecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drink solution, 24000 IU once per month
Study: NCT04219007
Drug: Vosoritide
Normalized name: VOSORITIDE
DrugBank: Vosoritide (DB11928)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
Study: NCT04482257
Drug: Irinotecan Liposome Injection combined with 5-FU/LV
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
Study: NCT00566995
Drug: ZACTIMA (Vandetanib) (ZD6474)
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01721993
Drug: T121
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02211079
Drug: JNJ-54861911
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.
Study: NCT02211079
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
Study: NCT02211079
Drug: Tolbutamide
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
Study: NCT01673217
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02657369
Drug: Lenvatinib 24 mg
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03854500
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
Study: NCT01868841
Drug: AdreView
Normalized name: AdreView
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 millicurie of AdreView (123I-mIBG)
Study: NCT00348010
Drug: Tramadol HCl ER
Normalized name: TRAMADOL HYDROCHLORIDE 100 mg ORAL TABLET, EXTENDED RELEASE [TRAMADOL HCL ER]
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02639065
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
Study: NCT01289080
Drug: OPC-34712
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally
Study: NCT00568997
Drug: Pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream
Study: NCT05853263
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol IV to substitute morphine IV.
Study: NCT05853263
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard care
Study: NCT05873738
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine patches
Study: NCT04626505
Drug: Ziltivekimab
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
Study: NCT03702621
Drug: liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL liposomal bupivacaine are injected into the liposomal bupivacaine group
Study: NCT03702621
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mL of 0.125% bupivacaine hydrochloride are injected into the liposomal bupivacaine group.~60mL of 0.25% bupivacaine hydrochloride are injected into the standard bupivacaine group
Study: NCT00102908
Drug: Zoledronate
Normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate infusion
Study: NCT00067236
Drug: PG-116800 (given as PG-530742)
Normalized name: PG
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
Study: NCT01913990
Drug: Dexamethasone, Ondansetron, Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
Study: NCT00927472
Drug: Malathion gel 0.5%
DrugBank: Malathion (DB00772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
Study: NCT00927472
Drug: Permethrin 1% rinse
Normalized name: PERMETHRIN 1% RINSE/0.25% SPRAY TOP,KIT
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
Study: NCT00297401
Drug: ruboxistaurin
Normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg, QD, PO, up to 8 weeks
Study: NCT03251417
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
Study: NCT03251417
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg oral take, daily
Study: NCT00726700
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00726700
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02630030
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01770964
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04596956
Drug: sodium bicarbonate Ringer injection
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in surgery
Study: NCT04596956
Drug: Lactated Ringer's solution
Normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in surgery
Study: NCT04332978
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01211171
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT02907996
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg tablet administered orally once daily
Study: NCT00048646
Drug: IV Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02352974
Drug: GAD-Alum
Normalized name: alum
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02352974
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00388596
Drug: SB-751689
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01466153
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
Study: NCT01466153
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
Study: NCT03424408
Drug: Aspirin 81 mg
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
Study: NCT02099175
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
Study: NCT02099175
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 - Concentrate for solution for infusion
Study: NCT02099175
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m2/day - Concentrate for solution for infusion
Study: NCT02099175
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2/day - Concentrate for solution for infusion
Study: NCT02099175
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2/day - Powder for solution for infusion
Study: NCT00080626
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg per meter-squared, every 14 days for 4 cycles
Study: NCT01939457
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01994031
Drug: Paclitaxel liposome injection
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01994031
Drug: Paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02213783
Drug: Imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
Study: NCT02213783
Drug: Imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
Study: NCT02143648
Drug: nalbuphine HCl ER tablets 60 mg BID
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
Study: NCT02143648
Drug: nalbuphine HCl ER tablets 120mg BID
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
Study: NCT01890993
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
Study: NCT02099175
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3000 mg/m2/day - Powder for solution for infusion
Study: NCT02998567
Drug: Guadecitabine
Normalized name: Guadecitabine
DrugBank: Guadecitabine (DB11918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In arm 1 (escalation) and 2 (expansion).
Study: NCT02998567
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In arm 1 (escalation) and 2 (expansion).
Study: NCT01195714
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
Study: NCT00768053
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50 mg once a week
Study: NCT03735446
Drug: Prexasertib
Normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint kinase 1 (CHK1) inhibitor
Study: NCT03735446
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard chemotherapy (topoisomerase inhibitor)
Study: NCT03735446
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy (topoisomerase II inhibitor)
Study: NCT03735446
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard chemotherapy (anti-metabolite)
Study: NCT01202591
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet oral once daily
Study: NCT01202591
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
Study: NCT00300274
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
Study: NCT00300274
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil supplied as 500 mg tablets.
Study: NCT00300274
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
Study: NCT03372044
Drug: PF-06865571 Immediate release suspension
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension
Study: NCT03372044
Drug: PF-06865571 Fast release MR tablets
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modified release tablets
Study: NCT03372044
Drug: PF-06865571 Immediate release tablets
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablets
Study: NCT04042701
Drug: Trastuzumab deruxtecan (DS-8201a)
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab.
Study: NCT04042701
Drug: Trastuzumab deruxtecan (DS-8201a)
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin.
Study: NCT02247544
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
Study: NCT01170650
Drug: EC145
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
Study: NCT01170650
Drug: EC20
Normalized name: Entecavir 20 mg
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
Study: NCT01456117
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone once daily for up to 14 days.
Study: NCT02811159
Drug: Telapristone acetate
Normalized name: Telapristone acetate
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
Study: NCT02453022
Drug: Danirixin HBr 50 mg IR Tablet
Normalized name: dextromethorphan
DrugBank: Danirixin (DB11922)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
Study: NCT02453022
Drug: Danirixin FB 50 mg IR Tablet
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
Study: NCT02453022
Drug: Prilosec (omeprazole) 40mg Delayed-Release capsule
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
Study: NCT00008177
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00008177
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally or IV
Study: NCT00008177
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally or IV
Study: NCT04042701
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
Study: NCT04421222
Drug: EPI-7386 (QD)
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose of EPI-7386
Study: NCT01213329
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
Study: NCT00150748
Drug: Levetiracetam 166 mg
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use
Study: NCT00150748
Drug: Levetiracetam 250 mg
Normalized name: levetiracetam 250 MG
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use
Study: NCT00150748
Drug: Levetiracetam 500 mg
Normalized name: levetiracetam 500 MG
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use
Study: NCT03270007
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: different from primary chemotherapy(containing anthracycline or paclitaxel)
Study: NCT03239522
Drug: Daprodustat 6 mg oral tablet
Normalized name: daprodustat 6 MG Oral Tablet
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: It is a 9.0 millimeter (mm) round, white film coated tablet.